Divestitures (Details) $ in Millions		3 Months Ended	11 Months Ended	12 Months Ended
	Nov. 29, 2022 USD ($)	Dec. 31, 2022 USD ($) Product	Nov. 29, 2022 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($) Product	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of assets and subsidiaries					$ 1,950.0	$ 96.7	$ 20.0
Revenue from disposal group					16,218.1	17,813.6	11,819.9
Impairment of goodwill					$ 117.0	0.0	0.0
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Nonoperating Income (Expense)
Number of insulin analog products | Product		3			3
Product rights and licenses
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment of intangible assets					$ 172.9	$ 83.4	$ 45.0
Biocon Biologics
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue from disposal group					(63.5)
Biocon Biologics | Scenario, Forecast | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Deferred cash consideration				$ 335.0
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Biocon Biologics
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration received on divestiture	$ 3,000.0		$ 3,000.0
Proceeds from sale of assets and subsidiaries	2,000.0
Equity consideration	$ 1,000.0
Ownership percentage	12.90%
Contingent liability (up to)	$ 250.0		250.0
Transition services agreement, revised term	2 years
Gain on divestiture of business	$ 1,750.0
Revenue from disposal group			$ 611.5
Disposal Group, Held-for-sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Possible impairment charges if assets held-for-sale are not sold in next fiscal year (in excess of)		$ 300.0			300.0
Disposal Group, Held-for-sale, Not Discontinued Operations | Upjohn Distributor Markets
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total impairment charge		374.2
Assets held-for-sale, intangible assets		230.3			230.3
Disposal Group, Held-for-sale, Not Discontinued Operations | Upjohn Distributor Markets | Inventories
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total impairment charge		$ 84.3
Disposal Group, Held-for-sale, Not Discontinued Operations | Upjohn Distributor Markets | Emerging Markets
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment of goodwill					$ 117.0